Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2026-07-15 20:58:14 ET · period of report 2026-07-13 · accession 0001933414-26-000100 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-07-15 20:58 | 2026-07-13 | MLYS | Congleton Jon | CEO, Dir | S - Sale | $27.24 | -10.7K | 603.6K | -2% | -$291.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-13 | S | D | 10,700 | $27.24 | 603,621 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on January 28, 2025. (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.80 to $27.58. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. |